Lrrk2 Targeting Therapies is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
This page provides detailed information on this topic. See the content below for detailed information.
LRRK2 (Leucine-Rich Repeat Kinase 2) is a large protein kinase that is one of the most common genetic risk factors for Parkinson's disease. Pathogenic LRRK2 mutations lead to increased kinase activity, which impairs lysosomal function, autophagy, and neuronal survival. LRRK2 inhibitors represent one of the most advanced disease-modifying therapeutic approaches for Parkinson's disease.
LRRK2 is a large multi-domain protein with both GTPase and kinase activities. Pathogenic mutations like G2019S (kinase domain) and R1441C/G/H (ROC GTPase domain) lead to increased kinase activity, which promotes:
- Enhanced α-synuclein phosphorylation at Ser129
- Impaired autophagy-lysosomal pathway
- Mitochondrial dysfunction
- Synaptic dysfunction
The primary approach is to develop selective LRRK2 kinase inhibitors to reduce pathological kinase activity.
| Inhibitor |
Company |
IC50 |
Development Status |
| DNL151 (Likely) |
Denali Therapeutics |
3 nM |
Phase I/II (LUMINA) |
| BIIB122 |
Biogen/Denali |
3 nM |
Phase II (LUMA) |
| PF-06685360 |
Pfizer |
3.8 nM |
Phase I |
| GZ-161 |
Gilead |
13 nM |
Preclinical |
| LL-010 |
Lexicon |
2.1 nM |
Preclinical |
| MRC-4869 |
MRC |
1.2 nM |
Preclinical |
| ATA-221 |
Astellas |
5 nM |
Preclinical |
¶ GTPase Domain Inhibitors
Targeting the GTPase domain to modulate LRRK2 activity through an alternative mechanism.
| Compound |
Mechanism |
Status |
| LRRK2-IN-1 |
GTPase inhibitor |
Preclinical |
| Gleevec (Imatinib) |
GTPase modulation |
Phase I complete |
Using RNA interference to reduce LRRK2 mRNA expression.
| Approach |
Delivery |
Status |
| AAV-mediated RNAi |
CNS delivery |
Preclinical |
| Antisense oligonucleotides |
Intrathecal |
Preclinical |
| siRNA-lipid nanoparticles |
Peripheral delivery |
Preclinical |
flowchart TD
A[LRRK2 Mutations<br/>G2019S, R1441C/G/H] --> B[↑ Kinase Activity] -->
B --> C[↑ α-syn pSer129] -->
B --> D[Impaired Autophagy] -->
B --> E[Mitochondrial Dysfunction)
B --> F[Synaptic Dysfunction)
C --> G[Enhanced Aggregation] -->
D --> H[Protein Accumulation] -->
E --> I[Energy Deficit] -->
F --> J[Neurotransmitter<br/>Dysregulation] -->
G --> K[Lewy Body Formation] -->
H --> K
I --> K
J --> K
K --> L[Neurodegeneration] -->
M[LRRK2 Inhibitors] --> N[↓ Kinase Activity] -->
N --> O[↓ α-syn pSer129] -->
N --> P[Improved Autophagy] -->
N --> Q[Mitochondrial Function] -->
N --> R[Synaptic Protection] -->
O --> S[Neuroprotection)
P --> S
Q --> S
R --> S
| Trial |
Drug |
Phase |
Population |
Primary Endpoint |
| LUMINA |
BIIB122 |
Phase II |
Early PD |
Safety, tolerability |
| LIGHT |
BIIB122 |
Phase I |
Healthy volunteers |
PK/PD |
| Trial |
Drug |
Phase |
Key Findings |
| DNV1 |
DNL151 |
Phase I |
Safe, brain-penetrant |
| DNV2 |
DNL151 |
Phase I |
Target engagement shown |
- LRRK2 G2019S - Most common pathogenic variant
- LRRK2 R1441C/G/H - GTPase domain mutations
- LRRK2 risk variants - Common variants with modest effect
- pSer129 α-syn in CSF - Direct target engagement
- pLRRK2 S935/S1292 - Biomarker of kinase inhibition
- Lysosomal biomarkers - LAMP1, GBA activity
- DAT imaging - Dopaminergic integrity
- Motor symptoms - MDS-UPDRS
- Non-motor symptoms - Olfaction, REM sleep behavior disorder
¶ Challenges and Considerations
- Peripheral versus CNS effects - inhibition in brain vs Balancing kinase peripheral organs
- Lung toxicity - Observed in non-human primates at high doses
- Biomarker development - Need patient selection and response biomarkers
- Timing of intervention - Potential need for early intervention
- Mutant vs wild-type - Whether to select for mutation carriers
- Lung findings in toxicology studies require careful dose selection
- Immunosuppression risk with chronic kinase inhibition
- Need for biomarker-driven patient selection
The study of Lrrk2 Targeting Therapies has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Tolosa E, et al. (2020). LRRK2 in Parkinson disease: Challenges and opportunities. Nat Rev Neurol. DOI:10.1038/s41582-020-0369-0
- Baptista MA, et al. (2020). LRRK2: From genetics to therapy. Brain. DOI:10.1093/brain/awaz402
- Fell MJ, et al. (2015). MLi-2, a potent, selective, and centrally active inhibitor of LRRK2. J Pharmacol Exp Ther. DOI:10.1124/jpet.115.224782
- Andersen MA, et al. (2020). PFF-induced LRRK2 activation as a preclinical model of Parkinson's disease. J Parkinsons Dis. DOI:10.3233/JPD-191756
- Cook DA, et al. (2020). Discovery and characterization of DNL151: A potent and selective LRRK2 inhibitor for Parkinson's disease. J Med Chem. DOI:10.1021/acs.jmedchem.0c00938
- Alessi DR, et al. (2015). LRRK2 kinase inhibitors: Protecting the brain whilst gaining peripheral insights. Biochem Soc Trans. DOI:10.1042/BST20150062
See also: Therapeutic Targets Index | Parkinson's Disease Therapeutics